

**PROPRANOLOL HYDROCHLORIDE- propranolol hydrochloride tablet
REMEDYREPACK INC.**


Propranolol Hydrochloride Tablets, USP

(10 mg, 20 mg, 40 mg, 60 mg and 80 mg)

Rx Only

DESCRIPTION

Propranolol hydrochloride, USP is a synthetic beta-adrenergic receptor blocking agent chemically described as 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, hydrochloride,(±)-. Its structural formula is:



Propranolol hydrochloride, USP is a stable, white to off-white, crystalline powder which is readily soluble in water and ethanol.

Propranolol Hydrochloride Tablets, USP are available as tablets for oral administration containing either 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg of propranolol hydrochloride, USP. Propranolol Hydrochloride Tablets, USP also contain lactose anhydrous, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. Color additives include FD&C Yellow no. 6 aluminum lake (10 mg and 80 mg), D&C Yellow no. 10 aluminum lake (10 mg, 40 mg, and 80 mg), FD&C Blue no. 1 aluminum lake (20 mg and 40 mg) and FD&C Red no. 40 aluminum lake (60 mg).

CLINICAL PHARMACOLOGY

General

Propranolol is a nonselective beta-adrenergic receptor blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic

receptor agonist agents for available receptor sites. When access to beta-receptor sites is blocked by propranolol, the chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation are decreased proportionately. At dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain.

Mechanism of Action

The mechanism of the antihypertensive effect of propranolol has not been established. Factors that may contribute to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use of propranolol. Effects of propranolol on plasma volume appear to be minor and somewhat variable.

In angina pectoris, propranolol generally reduces the oxygen requirement of the heart at any given level of effort by blocking the catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. Propranolol may increase oxygen requirements by increasing left ventricular fiber length, end diastolic pressure, and systolic ejection period. The net physiologic effect of beta-adrenergic blockade is usually advantageous and is manifested during exercise by delayed onset of pain and increased work capacity.

Propranolol exerts its antiarrhythmic effects in concentrations associated with beta-adrenergic blockade, and this appears to be its principal antiarrhythmic mechanism of action. In dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain.

The mechanism of the antimigraine effect of propranolol has not been established. Beta-adrenergic receptors have been demonstrated in the pial vessels of the brain.

The specific mechanism of propranolol's antitremor effects has not been established, but beta-2 (noncardiac) receptors may be involved. A central effect is also possible. Clinical studies have demonstrated that propranolol is of benefit in exaggerated physiological and essential (familial) tremor.

PHARMACOKINETICS AND DRUG METABOLISM

Absorption

Propranolol is highly lipophilic and almost completely absorbed after oral administration. However, it undergoes high first-pass metabolism by the liver and on average, only about 25% of propranolol reaches the systemic circulation. Peak plasma concentrations occur about 1 to 4 hours after an oral dose.

Administration of protein-rich foods increase the bioavailability of propranolol by about 50% with no change in time to peak concentration, plasma binding, half-life, or the amount of unchanged drug in the urine.

Distribution

Approximately 90% of circulating propranolol is bound to plasma proteins (albumin and α_1 acid glycoprotein). The binding is enantiomer-selective. The S(-)-enantiomer is preferentially bound to α_1 glycoprotein and the R(+)-enantiomer preferentially bound to albumin. The volume of distribution of propranolol is approximately 4 liters/kg.

Propranolol crosses the blood-brain barrier and the placenta, and is distributed into breast milk.

Metabolism and Elimination

Propranolol is extensively metabolized with most metabolites appearing in the urine. Propranolol is metabolized through three primary routes: aromatic hydroxylation (mainly 4-hydroxylation), N-dealkylation followed by further side-chain oxidation, and direct glucuronidation. It has been estimated that the percentage contributions of these routes to total metabolism are 42%, 41% and 17%, respectively, but with considerable variability between individuals. The four major metabolites are propranolol glucuronide, naphthyloxylactic acid and glucuronic acid, and sulfate conjugates of 4-hydroxy propranolol.

In vitro studies have indicated that the aromatic hydroxylation of propranolol is catalyzed mainly by polymorphic CYP2D6. Side-chain oxidation is mediated mainly by CYP1A2 and to some extent by CYP2D6. 4-hydroxy propranolol is a weak inhibitor of CYP2D6.

Propranolol is also a substrate of CYP2C19 and a substrate for the intestinal efflux transporter, p-glycoprotein (p-gp). Studies suggest however that p-gp is not dose-limiting for intestinal absorption of propranolol in the usual therapeutic dose range.

In healthy subjects, no difference was observed between CYP2D6 extensive metabolizers (EMs) and poor metabolizers (PMs) with respect to oral clearance or elimination half-life. Partial clearance of 4-hydroxy propranolol was significantly higher and of naphthyloxylactic acid significantly lower in EMs than PMs.

The plasma half-life of propranolol is from 3 to 6 hours.

Enantiomers

Propranolol is a racemic mixture of two enantiomers, R(+) and S(-). The S(-)-enantiomer is approximately 100 times as potent as the R(+)-enantiomer in blocking beta adrenergic receptors. In normal subjects receiving oral doses of racemic propranolol, S(-)-enantiomer concentrations exceeded those of the R(+)-enantiomer by 40% to 90% as a result of stereoselective hepatic metabolism. Clearance of the pharmacologically active S(-)-propranolol is lower than R(+)-propranolol after intravenous and oral doses.

Special Populations

Geriatric

In a study of 12 elderly (62 to 79 years old) and 12 young (25 to 33 years old) healthy subjects, the clearance of S(-)-enantiomer of propranolol was decreased in the elderly. Additionally, the half-life of both the R(+)- and S(-)-propranolol were prolonged in the elderly compared with the young (11 hours vs. 5 hours).

Clearance of propranolol is reduced with aging due to decline in oxidation capacity (ring oxidation and side-chain oxidation). Conjugation capacity remains unchanged. In a study of 32 patients age 30 to 84 years given a single 20-mg dose of propranolol, an inverse correlation was found between age and the partial metabolic clearances to 4-

hydroxypropranolol (40HP-ring oxidation) and to naphthoxylactic acid (NLA-side chain oxidation). No correlation was found between age and the partial metabolic clearance to propranolol glucuronide (PPLG-conjugation).

Gender

In a study of 9 healthy women and 12 healthy men, neither the administration of testosterone nor the regular course of the menstrual cycle affected the plasma binding of the propranolol enantiomers. In contrast, there was a significant, although non-enantioselective diminution of the binding of propranolol after treatment with ethinyl estradiol. These findings are inconsistent with another study, in which administration of testosterone cypionate confirmed the stimulatory role of this hormone on propranolol metabolism and concluded that the clearance of propranolol in men is dependent on circulating concentrations of testosterone. In women, none of the metabolic clearances for propranolol showed any significant association with either estradiol or testosterone.

Race

A study conducted in 12 Caucasian and 13 African-American male subjects taking propranolol, showed that at steady state, the clearance of R(+)- and S(-)-propranolol were about 76% and 53% higher in African-Americans than in Caucasians, respectively.

Chinese subjects had a greater proportion (18% to 45% higher) of unbound propranolol in plasma compared to Caucasians, which was associated with a lower plasma concentration of alpha₁acid glycoprotein.

Renal Insufficiency

In a study conducted in 5 patients with chronic renal failure, 6 patients on regular dialysis, and 5 healthy subjects, who received a single oral dose of 40 mg of propranolol, the peak plasma concentrations (C_{max}) of propranolol in the chronic renal failure group were 2 to 3-fold higher (161 ± 41 ng/mL) than those observed in the dialysis patients (47 ± 9 ng/mL) and in the healthy subjects (26 ± 1 ng/mL). Propranolol plasma clearance was also reduced in the patients with chronic renal failure.

Studies have reported a delayed absorption rate and a reduced half-life of propranolol in patients with renal failure of varying severity. Despite this shorter plasma half-life, propranolol peak plasma levels were 3 to 4 times higher and total plasma levels of metabolites were up to 3 times higher in these patients than in subjects with normal renal function.

Chronic renal failure has been associated with a decrease in drug metabolism via downregulation of hepatic cytochrome P450 activity resulting in a lower “first-pass” clearance.

Propranolol is not significantly dialyzable.

Hepatic Insufficiency

Propranolol is extensively metabolized by the liver. In a study conducted in 7 patients with cirrhosis and 9 healthy subjects receiving 80-mg oral propranolol every 8 hours for 7 doses, the steady-state unbound propranolol concentration in patients with cirrhosis was increased 3-fold in comparison to controls. In cirrhosis, the half-life increased to 11 hours compared to 4 hours (see **PRECAUTIONS**).

Drug Interactions

Interactions with Substrates, Inhibitors or Inducers of Cytochrome P-450 Enzymes

Because propranolol's metabolism involves multiple pathways in the cytochrome P-450 system (CYP2D6, 1A2, 2C19), co-administration with drugs that are metabolized by, or effect the activity (induction or inhibition) of one or more of these pathways may lead to clinically relevant drug interactions (see **Drug Interactions** under **PRECAUTIONS**).

Substrates or Inhibitors of CYP2D6

Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2D6, such as amiodarone, cimetidine, delavudin, fluoxetine, paroxetine, quinidine, and ritonavir. No interactions were observed with either ranitidine or lansoprazole.

Substrates or Inhibitors of CYP1A2

Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP1A2, such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan.

Substrates or Inhibitors of CYP2C19

Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2C19, such as fluconazole, cimetidine, fluoxetine, fluvoxamine, teniposide, and tolbutamide. No interaction was observed with omeprazole.

Inducers of Hepatic Drug Metabolism

Blood levels of propranolol may be decreased by co-administration with inducers such as rifampin, ethanol, phenytoin, and phenobarbital. Cigarette smoking also induces hepatic metabolism and has been shown to increase up to 77% the clearance of propranolol, resulting in decreased plasma concentrations.

Cardiovascular Drugs

Antiarrhythmics

The AUC of propafenone is increased by more than 200% by co-administration of propranolol.

The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade.

The metabolism of lidocaine is inhibited by co-administration of propranolol, resulting in a 25% increase in lidocaine concentrations.

Calcium Channel Blockers

The mean C_{max} and AUC of propranolol are increased, respectively, by 50% and 30% by co-administration of nisoldipine and by 80% and 47%, by co-administration of nifedipine.

The mean C_{max} and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol.

Propranolol does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol.

Non-Cardiovascular Drugs

Migraine Drugs

Administration of zolmitriptan or rizatriptan with propranolol resulted in increased concentrations of zolmitriptan (AUC increased by 56% and C_{max} by 37%) or rizatriptan (the AUC and C_{max} were increased by 67% and 75%, respectively).

Theophylline

Co-administration of theophylline with propranolol decreases theophylline oral clearance by 30% to 52%.

Benzodiazepines

Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites. Diazepam does not alter the pharmacokinetics of propranolol.

The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol.

Neuroleptic Drugs

Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.

Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level.

Anti-Ulcer Drugs

Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and C_{max} by 46% and 35%, respectively. Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.

Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol's pharmacokinetics.

Lipid Lowering Drugs

Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.

Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Propranolol did not have an effect on the pharmacokinetics of fluvastatin.

Warfarin

Concomitant administration of propranolol and warfarin has been shown to increase warfarin bioavailability and increase prothrombin time.

Alcohol

Concomitant use of alcohol may increase plasma levels of propranolol.

PHARMACODYNAMICS AND CLINICAL EFFECTS

Hypertension

In a retrospective, uncontrolled study, 107 patients with diastolic blood pressure 110 mmHg to 150 mmHg received propranolol 120 mg three times a day for at least 6 months, in addition to diuretics and potassium, but with no other antihypertensive agent. Propranolol contributed to control of diastolic blood pressure, but the magnitude of the effect of propranolol on blood pressure cannot be ascertained.

Angina Pectoris

In a double-blind, placebo-controlled study of 32 patients of both sexes, aged 32 to 69 years, with stable angina, propranolol 100 mg three times a day was administered for 4 weeks and shown to be more effective than placebo in reducing the rate of angina episodes and in prolonging total exercise time.

Atrial Fibrillation

In a report examining the long-term (5 to 22 months) efficacy of propranolol, 10 patients, aged 27 to 80, with atrial fibrillation and ventricular rate greater than 120 beats per minute despite digitalis, received propranolol up to 30 mg three times a day. Seven patients (70%) achieved ventricular rate reduction to less than 100 beats per minute.

Myocardial Infarction

The Beta-Blocker Heart Attack Trial (BHAT) was a National Heart, Lung and Blood Institute-sponsored multicenter, randomized, double-blind, placebo-controlled trial conducted in 31 U.S. centers (plus one in Canada) in 3,837 persons without history of severe congestive heart failure or presence of recent heart failure; certain conduction defects; angina since infarction, who had survived the acute phase of myocardial infarction. Propranolol was administered at either 60 mg or 80 mg three times a day based on blood levels achieved during an initial trial of 40 mg three times a day. Therapy with propranolol, begun 5 to 21 days following infarction, was shown to reduce overall mortality up to 39 months, the longest period of follow-up. This was primarily attributable to a reduction in cardiovascular mortality. The protective effect of propranolol was consistent regardless of age, sex, or site of infarction. Compared with placebo, total mortality was reduced 39% at 12 months and 26% over an average follow-up period of 25 months. The Norwegian Multicenter Trial in which propranolol was administered at 40 mg four times a day gave overall results which support the findings in the BHAT.

Although the clinical trials used either three times a day or four times a day dosing, clinical, pharmacologic, and pharmacokinetic data provide a reasonable basis for concluding that twice daily dosing with propranolol should be adequate in the treatment of postinfarction patients.

Migraine

In a 34-week, placebo-controlled, 4-period, dose-finding crossover study with a double-blind randomized treatment sequence, 62 patients with migraine received propranolol 20 mg to 80 mg 3 or 4 times daily. The headache unit index, a composite of the number of days with headache and the associated severity of the headache, was significantly reduced for patients receiving propranolol as compared to those on placebo.

Essential Tremor

In a 2 week, double-blind, parallel, placebo-controlled study of 9 patients with essential or familial tremor, propranolol, at a dose titrated as needed from 40 mg to 80 mg three times a day reduced tremor severity compared to placebo.

Hypertrophic Subaortic Stenosis

In an uncontrolled series of 13 patients with New York Heart Association (NYHA) class 2 or 3 symptoms and hypertrophic subaortic stenosis diagnosed at cardiac catheterization, oral propranolol 40 mg to 80 mg three times a day was administered and patients were followed for up to 17 months. Propranolol was associated with improved NYHA class for most patients.

Pheochromocytoma

In an uncontrolled series of 3 patients with norepinephrine-secreting pheochromocytoma who were pretreated with an alpha adrenergic blocker (prazosin), perioperative use of propranolol at doses of 40 mg to 80 mg three times a day resulted in symptomatic blood pressure control.

INDICATIONS AND USAGE

Hypertension

Propranolol hydrochloride tablets are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride is not indicated in the management of hypertensive emergencies.

Angina Pectoris Due to Coronary Atherosclerosis

Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris.

Atrial Fibrillation

Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response.

Myocardial Infarction

Propranolol is indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable.

Migraine

Propranolol is indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use.

Essential Tremor

Propranolol is indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol

causes a reduction in the tremor amplitude, but not in the tremor frequency. Propranolol is not indicated for the treatment of tremor associated with Parkinsonism.

Hypertrophic Subaortic Stenosis

Propranolol improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

Pheochromocytoma

Propranolol is indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors.

CONTRAINDICATIONS

Propranolol is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first degree block; 3) bronchial asthma; and 4) in patients with known hypersensitivity to propranolol hydrochloride.

WARNINGS

Angina Pectoris

There have been reports of exacerbation of angina and, in some cases, myocardial infarction, following abrupt discontinuance of propranolol therapy. Therefore, when discontinuance of propranolol is planned, the dosage should be gradually reduced over at least a few weeks and the patient should be cautioned against interruption or cessation of therapy without the physician's advice. If propranolol therapy is interrupted and exacerbation of angina occurs, it usually is advisable to reinstitute propranolol therapy and take other measures appropriate for the management of angina pectoris. Since coronary artery disease may be unrecognized, it may be prudent to follow the above advice in patients considered at risk of having occult atherosclerotic heart disease who are given propranolol for other indications.

Hypersensitivity and Skin Reactions

Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, have been associated with the administration of propranolol (see **ADVERSE REACTIONS**).

Cutaneous reactions, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and urticaria, have been reported with use of propranolol (see **ADVERSE REACTIONS**).

Cardiac Failure

Sympathetic stimulation may be a vital component supporting circulatory function in patients with congestive heart failure, and its inhibition by beta blockade may precipitate more severe failure. Although beta blockers should be avoided in overt congestive heart failure, some have been shown to be highly beneficial when used with close follow-up in patients with a history of failure who are well compensated and are receiving additional therapies, including diuretics as needed. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle.

In Patients without a History of Heart Failure, Continued use of beta blockers can, in some cases, lead to cardiac failure.

Nonallergic Bronchospasm (e.g., Chronic Bronchitis, Emphysema)

In general, patients with bronchospastic lung disease should not receive beta blockers. Propranolol should be administered with caution in this setting since it may provoke a bronchial asthmatic attack by blocking bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta-receptors.

Major Surgery

Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

Diabetes and Hypoglycemia

Beta-adrenergic blockade may prevent the appearance of certain premonitory signs and symptoms (pulse rate and pressure changes) of acute hypoglycemia, especially in labile insulin-dependent diabetics. In these patients, it may be more difficult to adjust the dosage of insulin.

Propranolol therapy, particularly when given to infants and children, diabetic or not, has been associated with hypoglycemia, especially during fasting as in preparation for surgery. Hypoglycemia has been reported in patients taking propranolol after prolonged physical exertion and in patients with renal insufficiency.

Thyrotoxicosis

Beta-adrenergic blockade may mask certain clinical signs of hyperthyroidism. Therefore, abrupt withdrawal of propranolol may be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. Propranolol may change thyroid-function tests, increasing T_4 and reverse T_3 and decreasing T_3 .

Wolff-Parkinson-White Syndrome

Beta-adrenergic blockade in patients with Wolf-Parkinson-White Syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker. In one case, this result was reported after an initial dose of 5 mg propranolol.

Pheochromocytoma

Blocking only the peripheral dilator (beta) action of epinephrine with propranolol leaves its constrictor (alpha) action unopposed. In the event of hemorrhage or shock, there is a disadvantage in having both beta and alpha blockade since the combination prevents the increase in heart rate and peripheral vasoconstriction needed to maintain blood pressure.

PRECAUTIONS

General

Propranolol should be used with caution in patients with impaired hepatic or renal function. Propranolol is not indicated for the treatment of hypertensive emergencies.

Beta-adrenergic receptor blockade can cause reduction of intraocular pressure. Patients should be told that propranolol may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.

While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

Clinical Laboratory Tests

In patients with hypertension, use of propranolol has been associated with elevated levels of serum potassium, serum transaminases and alkaline phosphatase. In severe heart failure, the use of propranolol has been associated with increases in Blood Urea Nitrogen.

Drug Interactions

Caution should be exercised when propranolol is administered with drugs that have an effect on CYP2D6, 1A2, or 2C19 metabolic pathways. Co-administration of such drugs with propranolol may lead to clinically relevant drug interactions and changes on its efficacy and/or toxicity (see **Drug Interactions** in **PHARMACOKINETICS AND DRUG METABOLISM**).

Cardiovascular Drugs

Antiarrhythmics

Propafenone has negative inotropic and beta-blocking properties that can be additive to those of propranolol.

Quinidine increases the concentration of propranolol and produces greater degrees of clinical beta-blockade and may cause postural hypotension.

Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with β -blockers such as propranolol.

The clearance of lidocaine is reduced with administration of propranolol. Lidocaine toxicity has been reported following co-administration with propranolol.

Caution should be exercised when administering propranolol with drugs that slow A-V nodal conduction, e.g. digitalis, lidocaine and calcium channel blockers.

Digitalis Glycosides

Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Calcium Channel Blockers

Caution should be exercised when patients receiving a beta blocker are administered a calcium-channel-blocking drug with negative inotropic and/or chronotropic effects. Both agents may depress myocardial contractility or atrioventricular conduction.

There have been reports of significant bradycardia, heart failure, and cardiovascular collapse with concurrent use of verapamil and beta-blockers.

Co-administration of propranolol and diltiazem in patients with cardiac disease has been associated with bradycardia, hypotension, high-degree heart block, and heart failure.

ACE Inhibitors

When combined with beta-blockers, ACE inhibitors can cause hypotension, particularly in the setting of acute myocardial infarction.

The antihypertensive effects of clonidine may be antagonized by beta-blockers. Propranolol should be administered cautiously to patients withdrawing from clonidine.

Alpha Blockers

Prazosin has been associated with prolongation of first dose hypotension in the presence of beta-blockers.

Postural hypotension has been reported in patients taking both beta-blockers and terazosin or doxazosin.

Reserpine

Patients receiving catecholamine-depleting drugs, such as reserpine, should be closely observed for excessive reduction of resting sympathetic nervous activity, which may result in hypotension, marked bradycardia, vertigo, syncopal attacks, or orthostatic hypotension.

Inotropic Agents

Patients on long-term therapy with propranolol may experience uncontrolled hypertension if administered epinephrine as a consequence of unopposed alpha-receptor stimulation. Epinephrine is therefore not indicated in the treatment of propranolol overdose (see **OVERDOSAGE**).

Isoproterenol and Dobutamine

Propranolol is a competitive inhibitor of beta-receptor agonists, and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. Also, propranolol may reduce sensitivity to dobutamine stress echocardiography in patients undergoing evaluation for myocardial ischemia.

Non-Cardiovascular Drugs

Nonsteroidal Anti-Inflammatory Drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to blunt the antihypertensive effect of beta-adrenoreceptor blocking agents.

Administration of indomethacin with propranolol may reduce the efficacy of propranolol in reducing blood pressure and heart rate.

Antidepressants

The hypotensive effects of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers by interfering with the beta blocking activity of propranolol.

Anesthetic Agents

Methoxyflurane and trichloroethylene may depress myocardial contractility when administered with propranolol.

Warfarin

Propranolol when administered with warfarin increases the concentration of warfarin. Prothrombin time, therefore, should be monitored.

Neuroleptic Drugs

Hypotension and cardiac arrest have been reported with the concomitant use of propranolol and haloperidol.

Thyroxine

Thyroxine may result in a lower than expected T₃ concentration when used concomitantly with propranolol.

Alcohol

Alcohol, when used concomitantly with propranolol, may increase plasma levels of propranolol.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In dietary administration studies in which mice and rats were treated with propranolol hydrochloride for up to 18 months at doses of up to 150 mg/kg/day, there was no evidence of drug-related tumorigenesis. On a body surface area basis, this dose in the mouse and rat is, respectively, about equal to and about twice the maximum recommended human oral daily dose (MRHD) of 640 mg propranolol hydrochloride. In a study in which both male and female rats were exposed to propranolol hydrochloride in their diets at concentrations of up to 0.05% (about 50 mg/kg body weight and less than the MRHD), from 60 days prior to mating and throughout pregnancy and lactation for two generations, there were no effects on fertility. Based on differing results from Ames Tests performed by different laboratories, there is equivocal evidence for a genotoxic effect of propranolol hydrochloride in bacteria (*S. typhimurium* strain TA 1538).

Pregnancy

In a series of reproductive and developmental toxicology studies, propranolol hydrochloride was given to rats by gavage or in the diet throughout pregnancy and lactation. At doses of 150 mg/kg/day, but not at doses of 80 mg/kg/day (equivalent to the MRHD on a body surface area basis), treatment was associated with embryotoxicity (reduced litter size and increased resorption rates) as well as neonatal toxicity (deaths). Propranolol hydrochloride also was administered (in the feed) to rabbits (throughout pregnancy and lactation) at doses as high as 150 mg/kg/day (about 5 times the maximum recommended human oral daily dose). No evidence of embryo or neonatal toxicity was noted.

There are no adequate and well-controlled studies in pregnant women. Intrauterine growth retardation, small placentas, and congenital abnormalities have been reported in neonates whose mothers received propranolol during pregnancy. Neonates whose mothers received propranolol at parturition have exhibited bradycardia, hypoglycemia, and/or respiratory depression. Adequate facilities for monitoring such infants at birth should be available. Propranolol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Propranolol is excreted in human milk. Caution should be exercised when propranolol is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of propranolol in pediatric patients have not been established.

Bronchospasm and congestive heart failure have been reported coincident with the administration of propranolol therapy in pediatric patients.

Geriatric Use

Clinical studies of propranolol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

ADVERSE REACTIONS

The following adverse events were observed and have been reported in patients using propranolol.

Cardiovascular

Bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.

Central Nervous System

Light-headedness, mental depression manifested by insomnia, lassitude, weakness, fatigue; catatonia; visual disturbances; hallucinations; vivid dreams; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. For immediate-release formulations, fatigue, lethargy, and vivid dreams appear dose-related.

Gastrointestinal

Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis.

Allergic

Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, pharyngitis and agranulocytosis; erythematous rash, fever combined with aching and sore throat; laryngospasm, and respiratory distress.

Respiratory

Bronchospasm.

Hematologic

Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.

Autoimmune

Systemic lupus erythematosus (SLE).

Skin and mucous membranes

Stevens-Johnson Syndrome, toxic epidermal necrolysis, dry eyes, exfoliative dermatitis, erythema multiforme, urticaria, alopecia, SLE-like reactions, and psoriasiform rashes. Oculomucocutaneous syndrome involving the skin, serous membranes and conjunctivae reported for a beta blocker (practolol) have not been associated with propranolol.

Genitourinary

Male impotence; Peyronie's disease.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Propranolol is not significantly dialyzable. In the event of overdosage or exaggerated response, the following measures should be employed:

General: If ingestion is or may have been recent, evacuate gastric contents, taking care to prevent pulmonary aspiration.

Supportive Therapy: Hypotension and bradycardia have been reported following propranolol overdose and should be treated appropriately. Glucagon can exert potent inotropic and chronotropic effects and may be particularly useful for the treatment of hypotension or depressed myocardial function after a propranolol overdose. Glucagon should be administered as 50 mcg/kg to 150 mcg/kg intravenously followed by continuous drip of 1 mg/hour to 5 mg/hour for positive chronotropic effect. Isoproterenol, dopamine or phosphodiesterase inhibitors may also be useful. Epinephrine, however, may provoke uncontrolled hypertension. Bradycardia can be treated with atropine or isoproterenol. Serious bradycardia may require temporary cardiac pacing.

The electrocardiogram, pulse, blood pressure, neurobehavioral status and intake and output balance must be monitored. Isoproterenol and aminophylline may be used for bronchospasm.

DOSAGE AND ADMINISTRATION

General

Because of the variable bioavailability of propranolol, the dose should be individualized based on response.

Hypertension

The usual initial dosage is 40 mg propranolol hydrochloride twice daily, whether used alone or added to a diuretic. Dosage may be increased gradually until adequate blood

pressure control is achieved. The usual maintenance dosage is 120 mg/day to 240 mg per day. In some instances a dosage of 640 mg a day may be required. The time needed for full antihypertensive response to a given dosage is variable and may range from a few days to several weeks.

While twice-daily dosing is effective and can maintain a reduction in blood pressure throughout the day, some patients, especially when lower doses are used, may experience a modest rise in blood pressure toward the end of the 12-hour dosing interval. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the day. If control is not adequate, a larger dose, or 3-times-daily therapy may achieve better control.

Angina Pectoris

Total daily doses of 80 mg to 320 mg propranolol hydrochloride, when administered orally, twice a day, three times a day, or four times a day, have been shown to increase exercise tolerance and to reduce ischemic changes in the ECG. If treatment is to be discontinued, reduce dosage gradually over a period of several weeks. (See

WARNINGS.)

Atrial Fibrillation

The recommended dose is 10 mg to 30 mg propranolol hydrochloride three or four times daily before meals and at bedtime.

Myocardial Infarction

In the Beta-Blocker Heart Attack Trial (BHAT), the initial dose was 40 mg three times a day, with titration after 1 month to 60 mg to 80 mg three times a day as tolerated. The recommended daily dosage is 180 mg to 240 mg propranolol hydrochloride per day in divided doses. Although a three times a day regimen was used in the BHAT and a four times a day regimen in the Norwegian Multicenter Trial, there is a reasonable basis for the use of either a three times a day or twice daily regimen (see

PHARMACODYNAMICS AND CLINICAL EFFECTS). The effectiveness and safety of daily dosages greater than 240 mg for prevention of cardiac mortality have not been established. However, higher dosages may be needed to effectively treat coexisting diseases such as angina or hypertension (see above).

Migraine

The initial dose is 80 mg propranolol hydrochloride daily in divided doses. The usual effective dose range is 160 mg to 240 mg per day. The dosage may be increased gradually to achieve optimum migraine prophylaxis. If a satisfactory response is not obtained within four to six weeks after reaching the maximum dose, propranolol therapy should be discontinued. It may be advisable to withdraw the drug gradually over a period of several weeks.

Essential Tremor

The initial dosage is 40 mg propranolol hydrochloride twice daily. Optimum reduction of essential tremor is usually achieved with a dose of 120 mg per day. Occasionally, it may be necessary to administer 240 mg to 320 mg per day.

Hypertrophic Subaortic Stenosis

The usual dosage is 20 mg to 40 mg propranolol hydrochloride three or four times daily before meals and at bedtime.

Pheochromocytoma

The usual dosage is 60 mg propranolol hydrochloride daily in divided doses for three days prior to surgery as adjunctive therapy to alpha-adrenergic blockade. For the management of inoperable tumors, the usual dosage is 30 mg daily in divided doses as adjunctive therapy to alpha-adrenergic blockade.

HOW SUPPLIED

Propranolol Hydrochloride Tablets, USP

10 mg – Orange, round, convex, debossed tablets on one side with PLIVA 467 and scored on the other side.

NDC: 70518-3281-00

NDC: 70518-3281-01

PACKAGING: 30 in 1 BLISTER PACK

PACKAGING: 30 in 1 BLISTER PACK

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

PROTECT FROM LIGHT.

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Repackaged and Distributed By:

Remedy Repack, Inc.

625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762

DRUG: Propranolol Hydrochloride

GENERIC: Propranolol Hydrochloride

DOSAGE: TABLET

ADMINISTRATION: ORAL

NDC: 70518-3281-0

NDC: 70518-3281-1

COLOR: orange

SHAPE: ROUND

SCORE: Two even pieces

SIZE: 6 mm

IMPRINT: PLIVA;467

PACKAGING: 30 in 1 BLISTER PACK

PACKAGING: 30 in 1 BLISTER PACK

ACTIVE INGREDIENT(S):

- PROPRANOLOL HYDROCHLORIDE 10mg in 1

INACTIVE INGREDIENT(S):

- ANHYDROUS LACTOSE
- MAGNESIUM STEARATE
- MICROCRYSTALLINE CELLULOSE
- SODIUM STARCH GLYCOLATE TYPE A POTATO
- FD&C YELLOW NO. 6
- D&C YELLOW NO. 10 ALUMINUM LAKE

Propranolol HCl Tablet

NDC #: 70518-3281-00

Expires:

LOT #:

Org NDC: 69238-2077-07

MFG: Amneal Pharma,
Ahmedabad, India 382220

10 mg

QTY: 30 Tablets

Round ORANGE PLIVA;467

Keep this and all medication out
of the reach of children
Store at 20-25°C (68-77°F);
excursions permitted to 15-30°C
(59-86°F) [See USP]

Usual Dosage: See Insert



RX ONLY

Repackaged By:
RemedyRepack Inc.,
Indiana, PA 15701, 724.465.8762

USP 231, 232, 233
USP 234, 235, 236
USP 237, 238, 239
USP 240, 241, 242
USP 243, 244, 245
USP 246, 247, 248
USP 249, 250, 251
USP 252, 253, 254
USP 255, 256, 257
USP 258, 259, 260
USP 261, 262, 263
USP 264, 265, 266
USP 267, 268, 269
USP 270, 271, 272
USP 273, 274, 275
USP 276, 277, 278
USP 279, 280, 281
USP 282, 283, 284
USP 285, 286, 287
USP 288, 289, 290
USP 291, 292, 293
USP 294, 295, 296
USP 297, 298, 299
USP 300, 301, 302
USP 303, 304, 305
USP 306, 307, 308
USP 309, 310, 311
USP 312, 313, 314
USP 315, 316, 317
USP 318, 319, 320
USP 321, 322, 323
USP 324, 325, 326
USP 327, 328, 329
USP 330, 331, 332
USP 333, 334, 335
USP 336, 337, 338
USP 339, 340, 341
USP 342, 343, 344
USP 345, 346, 347
USP 348, 349, 350
USP 351, 352, 353
USP 354, 355, 356
USP 357, 358, 359
USP 360, 361, 362
USP 363, 364, 365
USP 366, 367, 368
USP 369, 370, 371
USP 372, 373, 374
USP 375, 376, 377
USP 378, 379, 380
USP 381, 382, 383
USP 384, 385, 386
USP 387, 388, 389
USP 390, 391, 392
USP 393, 394, 395
USP 396, 397, 398
USP 399, 400, 401
USP 402, 403, 404
USP 405, 406, 407
USP 408, 409, 410
USP 411, 412, 413
USP 414, 415, 416
USP 417, 418, 419
USP 420, 421, 422
USP 423, 424, 425
USP 426, 427, 428
USP 429, 430, 431
USP 432, 433, 434
USP 435, 436, 437
USP 438, 439, 440
USP 441, 442, 443
USP 444, 445, 446
USP 447, 448, 449
USP 450, 451, 452
USP 453, 454, 455
USP 456, 457, 458
USP 459, 460, 461
USP 462, 463, 464
USP 465, 466, 467
USP 468, 469, 470
USP 471, 472, 473
USP 474, 475, 476
USP 477, 478, 479
USP 480, 481, 482
USP 483, 484, 485
USP 486, 487, 488
USP 489, 490, 491
USP 492, 493, 494
USP 495, 496, 497
USP 498, 499, 500
USP 501, 502, 503
USP 504, 505, 506
USP 507, 508, 509
USP 510, 511, 512
USP 513, 514, 515
USP 516, 517, 518
USP 519, 520, 521
USP 522, 523, 524
USP 525, 526, 527
USP 528, 529, 530
USP 531, 532, 533
USP 534, 535, 536
USP 537, 538, 539
USP 540, 541, 542
USP 543, 544, 545
USP 546, 547, 548
USP 549, 550, 551
USP 552, 553, 554
USP 555, 556, 557
USP 558, 559, 560
USP 561, 562, 563
USP 564, 565, 566
USP 567, 568, 569
USP 570, 571, 572
USP 573, 574, 575
USP 576, 577, 578
USP 579, 580, 581
USP 582, 583, 584
USP 585, 586, 587
USP 588, 589, 590
USP 591, 592, 593
USP 594, 595, 596
USP 597, 598, 599
USP 600, 601, 602
USP 603, 604, 605
USP 606, 607, 608
USP 609, 610, 611
USP 612, 613, 614
USP 615, 616, 617
USP 618, 619, 620
USP 621, 622, 623
USP 624, 625, 626
USP 627, 628, 629
USP 630, 631, 632
USP 633, 634, 635
USP 636, 637, 638
USP 639, 640, 641
USP 642, 643, 644
USP 645, 646, 647
USP 648, 649, 650
USP 651, 652, 653
USP 654, 655, 656
USP 657, 658, 659
USP 660, 661, 662
USP 663, 664, 665
USP 666, 667, 668
USP 669, 670, 671
USP 672, 673, 674
USP 675, 676, 677
USP 678, 679, 680
USP 681, 682, 683
USP 684, 685, 686
USP 687, 688, 689
USP 690, 691, 692
USP 693, 694, 695
USP 696, 697, 698
USP 699, 700, 701
USP 702, 703, 704
USP 705, 706, 707
USP 708, 709, 710
USP 711, 712, 713
USP 714, 715, 716
USP 717, 718, 719
USP 720, 721, 722
USP 723, 724, 725
USP 726, 727, 728
USP 729, 730, 731
USP 732, 733, 734
USP 735, 736, 737
USP 738, 739, 740
USP 741, 742, 743
USP 744, 745, 746
USP 747, 748, 749
USP 750, 751, 752
USP 753, 754, 755
USP 756, 757, 758
USP 759, 760, 761
USP 762, 763, 764
USP 765, 766, 767
USP 768, 769, 770
USP 771, 772, 773
USP 774, 775, 776
USP 777, 778, 779
USP 780, 781, 782
USP 783, 784, 785
USP 786, 787, 788
USP 789, 790, 791
USP 792, 793, 794
USP 795, 796, 797
USP 798, 799, 800
USP 801, 802, 803
USP 804, 805, 806
USP 807, 808, 809
USP 810, 811, 812
USP 813, 814, 815
USP 816, 817, 818
USP 819, 820, 821
USP 822, 823, 824
USP 825, 826, 827
USP 828, 829, 830
USP 831, 832, 833
USP 834, 835, 836
USP 837, 838, 839
USP 840, 841, 842
USP 843, 844, 845
USP 846, 847, 848
USP 849, 850, 851
USP 852, 853, 854
USP 855, 856, 857
USP 858, 859, 860
USP 861, 862, 863
USP 864, 865, 866
USP 867, 868, 869
USP 870, 871, 872
USP 873, 874, 875
USP 876, 877, 878
USP 879, 880, 881
USP 882, 883, 884
USP 885, 886, 887
USP 888, 889, 890
USP 891, 892, 893
USP 894, 895, 896
USP 897, 898, 899
USP 900, 901, 902
USP 903, 904, 905
USP 906, 907, 908
USP 909, 910, 911
USP 912, 913, 914
USP 915, 916, 917
USP 918, 919, 920
USP 921, 922, 923
USP 924, 925, 926
USP 927, 928, 929
USP 930, 931, 932
USP 933, 934, 935
USP 936, 937, 938
USP 939, 940, 941
USP 942, 943, 944
USP 945, 946, 947
USP 948, 949, 950
USP 951, 952, 953
USP 954, 955, 956
USP 957, 958, 959
USP 960, 961, 962
USP 963, 964, 965
USP 966, 967, 968
USP 969, 970, 971
USP 972, 973, 974
USP 975, 976, 977
USP 978, 979, 980
USP 981, 982, 983
USP 984, 985, 986
USP 987, 988, 989
USP 990, 991, 992
USP 993, 994, 995
USP 996, 997, 998
USP 999, 1000, 1001
USP 1002, 1003, 1004
USP 1005, 1006, 1007
USP 1008, 1009, 1010
USP 1011, 1012, 1013
USP 1014, 1015, 1016
USP 1017, 1018, 1019
USP 1020, 1021, 1022
USP 1023, 1024, 1025
USP 1026, 1027, 1028
USP 1029, 1030, 1031
USP 1032, 1033, 1034
USP 1035, 1036, 1037
USP 1038, 1039, 1040
USP 1041, 1042, 1043
USP 1044, 1045, 1046
USP 1047, 1048, 1049
USP 1050, 1051, 1052
USP 1053, 1054, 1055
USP 1056, 1057, 1058
USP 1059, 1060, 1061
USP 1062, 1063, 1064
USP 1065, 1066, 1067
USP 1068, 1069, 1070
USP 1071, 1072, 1073
USP 1074, 1075, 1076
USP 1077, 1078, 1079
USP 1080, 1081, 1082
USP 1083, 1084, 1085
USP 1086, 1087, 1088
USP 1089, 1090, 1091
USP 1092, 1093, 1094
USP 1095, 1096, 1097
USP 1098, 1099, 1100
USP 1101, 1102, 1103
USP 1104, 1105, 1106
USP 1107, 1108, 1109
USP 1110, 1111, 1112
USP 1113, 1114, 1115
USP 1116, 1117, 1118
USP 1119, 1120, 1121
USP 1122, 1123, 1124
USP 1125, 1126, 1127
USP 1128, 1129, 1130
USP 1131, 1132, 1133
USP 1134, 1135, 1136
USP 1137, 1138, 1139
USP 1140, 1141, 1142
USP 1143, 1144, 1145
USP 1146, 1147, 1148
USP 1149, 1150, 1151
USP 1152, 1153, 1154
USP 1155, 1156, 1157
USP 1158, 1159, 1160
USP 1161, 1162, 1163
USP 1164, 1165, 1166
USP 1167, 1168, 1169
USP 1170, 1171, 1172
USP 1173, 1174, 1175
USP 1176, 1177, 1178
USP 1179, 1180, 1181
USP 1182, 1183, 1184
USP 1185, 1186, 1187
USP 1188, 1189, 1190
USP 1191, 1192, 1193
USP 1194, 1195, 1196
USP 1197, 1198, 1199
USP 1200, 1201, 1202
USP 1203, 1204, 1205
USP 1206, 1207, 1208
USP 1209, 1210, 1211
USP 1212, 1213, 1214
USP 1215, 1216, 1217
USP 1218, 1219, 1220
USP 1221, 1222, 1223
USP 1224, 1225, 1226
USP 1227, 1228, 1229
USP 1230, 1231, 1232
USP 1233, 1234, 1235
USP 1236, 1237, 1238
USP 1239, 1240, 1241
USP 1242, 1243, 1244
USP 1245, 1246, 1247
USP 1248, 1249, 1250
USP 1251, 1252, 1253
USP 1254, 1255, 1256
USP 1257, 1258, 1259
USP 1260, 1261, 1262
USP 1263, 1264, 1265
USP 1266, 1267, 1268
USP 1269, 1270, 1271
USP 1272, 1273, 1274
USP 1275, 1276, 1277
USP 1278, 1279, 1280
USP 1281, 1282, 1283
USP 1284, 1285, 1286
USP 1287, 1288, 1289
USP 1290, 1291, 1292
USP 1293, 1294, 1295
USP 1296, 1297, 1298
USP 1299, 1300, 1301
USP 1302, 1303, 1304
USP 1305, 1306, 1307
USP 1308, 1309, 1310
USP 1311, 1312, 1313
USP 1314, 1315, 1316
USP 1317, 1318, 1319
USP 1320, 1321, 1322
USP 1323, 1324, 1325
USP 1326, 1327, 1328
USP 1329, 1330, 1331
USP 1332, 1333, 1334
USP 1335, 1336, 1337
USP 1338, 1339, 1340
USP 1341, 1342, 1343
USP 1344, 1345, 1346
USP 1347, 1348, 1349
USP 1350, 1351, 1352
USP 1353, 1354, 1355
USP 1356, 1357, 1358
USP 1359, 1360, 1361
USP 1362, 1363, 1364
USP 1365, 1366, 1367
USP 1368, 1369, 1370
USP 1371, 1372, 1373
USP 1374, 1375, 1376
USP 1377, 1378, 1379
USP 1380, 1381, 1382
USP 1383, 1384, 1385
USP 1386, 1387, 1388
USP 1389, 1390, 1391
USP 1392, 1393, 1394
USP 1395, 1396, 1397
USP 1398, 1399, 1400
USP 1401, 1402, 1403
USP 1404, 1405, 1406
USP 1407, 1408, 1409
USP 1410, 1411, 1412
USP 1413, 1414, 1415
USP 1416, 1417, 1418
USP 1419, 1420, 1421
USP 1422, 1423, 1424
USP 1425, 1426, 1427
USP 1428, 1429, 1430
USP 1431, 1432, 1433
USP 1434, 1435, 1436
USP 1437, 1438, 1439
USP 1440, 1441, 1442
USP 1443, 1444, 1445
USP 1446, 1447, 1448
USP 1449, 1450, 1451
USP 1452, 1453, 1454
USP 1455, 1456, 1457
USP 1458, 1459, 1460
USP 1461, 1462, 1463
USP 1464, 1465, 1466
USP 1467, 1468, 1469
USP 1470, 1471, 1472
USP 1473, 1474, 1475
USP 1476, 1477, 1478
USP 1479, 1480, 1481
USP 1482, 1483, 1484
USP 1485, 1486, 1487
USP 1488, 1489, 1490
USP 1491, 1492, 1493
USP 1494, 1495, 1496
USP 1497, 1498, 1499
USP 1500, 1501, 1502
USP 1503, 1504, 1505
USP 1506, 1507, 1508
USP 1509, 1510, 1511
USP 1512, 1513, 1514
USP 1515, 1516, 1517
USP 1518, 1519, 1520
USP 1521, 1522, 1523
USP 1524, 1525, 1526
USP 1527, 1528, 1529
USP 1530, 1531, 1532
USP 1533, 1534, 1535
USP 1536, 1537, 1538
USP 1539, 1540, 1541
USP 1542, 1543, 1544
USP 1545, 1546, 1547
USP 1548, 1549, 1550
USP 1551, 1552, 1553
USP 1554, 1555, 1556
USP 1557, 1558, 1559
USP 1560, 1561, 1562
USP 1563, 1564, 1565
USP 1566, 1567, 1568
USP 1569, 1570, 1571
USP 1572, 1573, 1574
USP 1575, 1576, 1577
USP 1578, 1579, 1580
USP 1581, 1582, 1583
USP 1584, 1585, 1586
USP 1587, 1588, 1589
USP 1590, 1591, 1592
USP 1593, 1594, 1595
USP 1596, 1597, 1598
USP 1599, 1600, 1601
USP 1602, 1603, 1604
USP 1605, 1606, 1607
USP 1608, 1609, 1610
USP 1611, 1612, 1613
USP 1614, 1615, 1616
USP 1617, 1618, 1619
USP 1620, 1621, 1622
USP 1623, 1624, 1625
USP 1626, 1627, 1628
USP 1629, 1630, 1631
USP 1632, 1633, 1634
USP 1635, 1636, 1637
USP 1638, 1639, 1640
USP 1641, 1642, 1643
USP 1644, 1645, 1646
USP 1647, 1648, 1649
USP 1650, 1651, 1652
USP 1653, 1654, 1655
USP 1656, 1657, 1658
USP 1659, 1660, 1661
USP 1662, 1663, 1664
USP 1665, 1666, 1667
USP 1668, 1669, 1670
USP 1671, 1672, 1673
USP 1674, 1675, 1676
USP 1677, 1678, 1679
USP 1680, 1681, 1682
USP 1683, 1684, 1685
USP 1686, 1687, 1688
USP 1689, 1690, 1691
USP 1692, 1693, 1694
USP 1695, 1696, 1697
USP 1698, 1699, 1700
USP 1701, 1702, 1703
USP 1704, 1705, 1706
USP 1707, 1708, 1709
USP 1710, 1711, 1712
USP 1713, 1714, 1715
USP 1716, 1717, 1718
USP 1719, 1720, 1721
USP 1722, 1723, 1724
USP 1725, 1726, 1727
USP 1728, 1729, 1730
USP 1731, 1732, 1733
USP 1734, 1735, 1736
USP 1737, 1738, 1739
USP 1740, 1741, 1742
USP 1743, 1744, 1745
USP 1746, 1747, 1748
USP 1749, 1750, 1751
USP 1752, 1753, 1754
USP 1755, 1756, 1757
USP 1758, 1759, 1760
USP 1761, 1762, 1763
USP 1764, 1765, 1766
USP 1767, 1768, 1769
USP 1770, 1771, 1772
USP 1773, 1774, 1775
USP 1776, 1777, 1778
USP 1779, 1780, 1781
USP 1782, 1783, 1784
USP 1785, 1786, 1787
USP 1788, 1789, 1790
USP 1791, 1792, 1793
USP 1794, 1795, 1796
USP 1797, 1798, 1799
USP 1800, 1801, 1802
USP 1803, 1804, 1805
USP 1806, 1807, 1808
USP 1809, 1810, 1811
USP 1812, 1813, 1814
USP 1815, 1816, 1817
USP 1818, 1819, 1820
USP 1821, 1822, 1823
USP 1824, 1825, 1826
USP 1827, 1828, 1829
USP 1830, 1831, 1832
USP 1833, 1834, 1835
USP 1836, 1837, 1838
USP 1839, 1840, 1841
USP 1842, 1843, 1844
USP 1845, 1846, 1847
USP 1848, 1849, 1850
USP 1851, 1852, 1853
USP 1854, 1855, 1856
USP 1857, 1858, 1859
USP 1860, 1861, 1862
USP 1863, 1864, 1865
USP 1866, 1867, 1868
USP 1869, 1870, 1871
USP 1872, 1873, 1874
USP 1875, 1876, 1877
USP 1878, 1879, 1880
USP 1881, 1882, 1883
USP 1884, 1885, 1886
USP 1887, 1888, 1889
USP 1890, 1891, 1892
USP 1893, 1894, 1895
USP 1896, 1897, 1898
USP 1899, 1900, 1901
USP 1902, 1903, 1904
USP 1905, 1906, 1907
USP 1908, 1909, 1910
USP 1911, 1912, 1913
USP 1914, 1915, 1916
USP 1917, 1918, 1919
USP 1920, 1921, 1922
USP 1923, 1924, 1925
USP 1926, 1927, 1928
USP 1929, 1930, 1931
USP 1932, 1933, 1934
USP 1935, 1936, 1937
USP 1938, 1939, 1940
USP 1941, 1942, 1943
USP 1944, 1945, 1946
USP 1947, 1948, 1949
USP 1950, 1951, 1952
USP

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70518-3281(NDC:69238-2077)	
Route of Administration	ORAL			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
PROPRANOLOL HYDROCHLORIDE (UNII: F8A3652H1V) (PROPRANOLOL - UNII:9Y8NXQ24VQ)		PROPRANOLOL HYDROCHLORIDE	10 mg	
Inactive Ingredients				
Ingredient Name			Strength	
ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)				
MAGNESIUM STEARATE (UNII: 70097M6I30)				
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)				
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)				
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)				
D&C YELLOW NO. 10 ALUMINUM LAKE (UNII: CQ3XH3DET6)				
Product Characteristics				
Color	orange	Score	2 pieces	
Shape	ROUND	Size	6mm	
Flavor		Imprint Code	PLIVA;467	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70518-3281-0	30 in 1 BLISTER PACK; Type 0: Not a Combination Product	12/03/2021	
2	NDC:70518-3281-1	30 in 1 BLISTER PACK; Type 0: Not a Combination Product	02/07/2025	
Marketing Information				
Marketing Category	Application Number or Monograph Citation		Marketing Start Date	Marketing End Date
ANDA	ANDA071972		12/03/2021	

Labeler - REMEDYREPACK INC. (829572556)